Samuel Kintz
Patrimonio netto: 36 M $ in data 31/07/2026
Patrimonio netto: 36 M $ in data 31/07/2026
Samuel S.
Kintz is the founder of Enliven Therapeutics, Inc., founded in 2019, where the title held is Head-Pipeline.
Mr. Kintz is also the founder of Enliven Therapeutics, Inc...
Mr. Kintz was Senior Director-Strategy & Business Development at Stemcentrx, Inc. from 2016 to 2019.
Mr. Kintz was Head-Research at AbbVie Stemcentrx LLC from 2016 to 2019.
Mr. Kintz was Head-Medicinal Chemist at Genentech, Inc. Mr. Kintz was Vice President-Business Development & Applications at BlueLight Therapeutics, Inc. Mr. Kintz completed undergraduate and MBA degrees at Stanford University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 652.892 ( 0,91% ) | 36 M $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Fondatore | 01/06/2019 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Fondatore | - |
| Società | Posizione | Fine |
|---|---|---|
AbbVie Stemcentrx LLC | Corporate Officer/Principal | 01/06/2019 |
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Develops life-changing therapies for cancer patients | Corporate Officer/Principal | 01/06/2019 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
BlueLight Therapeutics, Inc.
BlueLight Therapeutics, Inc. BiotechnologyHealth Technology Develops novel systems to analyze real-time protein function for research and clinical applications | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 7 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
BlueLight Therapeutics, Inc.
BlueLight Therapeutics, Inc. BiotechnologyHealth Technology Develops novel systems to analyze real-time protein function for research and clinical applications | Health Technology |
Stemcentrx, Inc.
Stemcentrx, Inc. BiotechnologyHealth Technology Develops life-changing therapies for cancer patients | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbbVie Stemcentrx LLC | |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology Engages in discovery and development of small molecule treatments for cancer | Health Technology |
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale